Oxford Cancer Biomarkers Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 11

Oxford Cancer Biomarkers General Information

Description

Developer of predictive biomarker diagnostic tests designed to advance personalized medicine within oncology, colorectal cancer and its treatments. The company's tests indicate dihydropyridine dehydrogenase deficiency and variants detected strongly associated with partial dihydropyrimidine deficiency as well as the increased risk of toxicity grades, enabling doctors and patients to examine resected tissue samples and identify the risk of relapse before it happens.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • C/o Douglas Mcdonald Ca
  • 2 Octavia Buildings
  • Kilmacolm PA13 4AE
  • Scotland, United Kingdom
+44 01865
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Diagnostic Equipment
Vertical(s)
Corporate Office
  • C/o Douglas Mcdonald Ca
  • 2 Octavia Buildings
  • Kilmacolm PA13 4AE
  • Scotland, United Kingdom
+44 01865

Oxford Cancer Biomarkers Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oxford Cancer Biomarkers Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 03-Apr-2023 Completed Generating Revenue
10. Grant 03-Mar-2023 Completed Generating Revenue
9. Later Stage VC 03-Jun-2019 Completed Generating Revenue
8. Later Stage VC 29-May-2019 Completed Generating Revenue
7. Later Stage VC 08-May-2017 Completed Generating Revenue
6. Later Stage VC 15-Nov-2016 Completed Generating Revenue
5. Later Stage VC 14-Dec-2015 Completed Generating Revenue
4. Early Stage VC 01-Jan-2013 Completed Generating Revenue
3. Early Stage VC 18-Jan-2012 $4.65M $4.65M Completed Startup
2. Early Stage VC 01-Jan-2011 Completed Startup
To view Oxford Cancer Biomarkers’s complete valuation and funding history, request access »

Oxford Cancer Biomarkers Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 4,972 $1.287292 $233 $233 1x $233 33.75%
Ordinary 759 $1.287292 $5088.11 $5088.11 1x $5088.11 5.15%
To view Oxford Cancer Biomarkers’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Oxford Cancer Biomarkers Patents

Oxford Cancer Biomarkers Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4645338-A1 Histopathology-based solid tumour analysis Inactive 03-May-2024
GB-202406267-D0 Histopathology-based solid tumour analysis Pending 03-May-2024
GB-2640747-A Histopathology-based solid tumour analysis Pending 03-May-2024
US-20250342974-A1 Histopathology-based solid tumour analysis Pending 03-May-2024
EP-3271864-A1 Tissue sample analysis technique Active 18-Mar-2015 A61B10/0241
To view Oxford Cancer Biomarkers’s complete patent history, request access »

Oxford Cancer Biomarkers Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oxford Cancer Biomarkers Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Panacea Capital Venture Capital Minority
NHS England Government
Kwang Dong Pharmaceutical Corporation Minority
Plutus Investment Group Family Office Minority
You’re viewing 5 of 11 investors. Get the full list »

Oxford Cancer Biomarkers FAQs

  • When was Oxford Cancer Biomarkers founded?

    Oxford Cancer Biomarkers was founded in 2010.

  • Where is Oxford Cancer Biomarkers headquartered?

    Oxford Cancer Biomarkers is headquartered in Kilmacolm, United Kingdom.

  • What is the size of Oxford Cancer Biomarkers?

    Oxford Cancer Biomarkers has 6 total employees.

  • What industry is Oxford Cancer Biomarkers in?

    Oxford Cancer Biomarkers’s primary industry is Discovery Tools (Healthcare).

  • Is Oxford Cancer Biomarkers a private or public company?

    Oxford Cancer Biomarkers is a Private company.

  • What is Oxford Cancer Biomarkers’s current revenue?

    The current revenue for Oxford Cancer Biomarkers is .

  • How much funding has Oxford Cancer Biomarkers raised over time?

    Oxford Cancer Biomarkers has raised $23.4M.

  • Who are Oxford Cancer Biomarkers’s investors?

    , Panacea Capital, NHS England, Kwang Dong Pharmaceutical, and Plutus Investment Group are 5 of 11 investors who have invested in Oxford Cancer Biomarkers.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process